In this week's edition, CAR-T 'robustly effective' in younger patients with deadly form of brain cancer; SARS-CoV-2 linked to range of neurological diseases; Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability; and more. Read the full coverage here: Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use CAR-T 'robustly effective' in younger patients with deadly form of brain cancer SARS-CoV-2 linked to range of neurological diseases Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability References: Press Release Majzner RG, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans. Klein RS, et al. Neurobiology of COVID-19. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle. Cukierman-Yaffe T, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac200 Dybjer E, et al. Diabet Med. 2022;doi:10.1111/dme.14806.

Ver todos los episodios